KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Tax Provisions (2016 - 2025)

Ionis Pharmaceuticals has reported Tax Provisions over the past 16 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Tax Provisions at $1.5 million for Q4 2025, up 155.34% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (up 129.04% YoY), and the annual figure for FY2025 was $1.8 million, up 128.94%.
  • Tax Provisions for Q4 2025 was $1.5 million at Ionis Pharmaceuticals, up from $213000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for IONS hit a ceiling of $11.4 million in Q1 2023 and a floor of -$3.6 million in Q3 2024.
  • Median Tax Provisions over the past 5 years was $293000.0 (2021), compared with a mean of $2.0 million.
  • Biggest five-year swings in Tax Provisions: surged 2573.27% in 2022 and later tumbled 154.86% in 2024.
  • Ionis Pharmaceuticals' Tax Provisions stood at $303000.0 in 2021, then surged by 2573.27% to $8.1 million in 2022, then fell by 19.8% to $6.5 million in 2023, then crashed by 141.12% to -$2.7 million in 2024, then surged by 155.34% to $1.5 million in 2025.
  • The last three reported values for Tax Provisions were $1.5 million (Q4 2025), $213000.0 (Q3 2025), and -$20000.0 (Q2 2025) per Business Quant data.